The limits of oral therapy in pulmonary arterial hypertension management

References

• RubinLJPrimary pulmonary hypertension[J]N Engl J Med199733621111178988890
   PubMed Web of Science ®Google Scholar
• SimonneauGGatzoulisMAAdatiaIUpdated clinical classification of pulmonary hypertension[J]J Am Coll Cardiol20136225 SupplD34D4124355639
   PubMed Web of Science ®Google Scholar
• RichSDantzkerDRAyresSMPrimary pulmonary hypertension. A national prospective study[J]Ann Intern Med198710722162233605900
   PubMed Web of Science ®Google Scholar
• D’AlonzoGEBarstRJAyresSMSurvival in patients with primary pulmonary hypertension. Results from a national prospective registry[J]Ann Intern Med199111553433491863023
   PubMed Web of Science ®Google Scholar
• GalieNHoeperMMHumbertMGuidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT) [J]Eur Heart J200930202493253719713419
   PubMed Web of Science ®Google Scholar
• HumbertMSitbonOChaouatASurvival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era[J]Circulation2010122215616320585011
   PubMed Web of Science ®Google Scholar
• GalieNCorrisPAFrostAUpdated treatment algorithm of pulmonary arterial hypertension[J]J Am Coll Cardiol20136225 SupplD60D7224355643
   PubMed Web of Science ®Google Scholar
• GalieNManesANegroLA meta-analysis of randomized controlled trials in pulmonary arterial hypertension[J]Eur Heart J200930439440319155250
   PubMed Web of Science ®Google Scholar
• RubinLJMendozaJHoodMTreatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial[J]Ann Intern Med199011274854912107780
   PubMed Web of Science ®Google Scholar
• BarstRJRubinLJLongWAA comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension[J]N Engl J Med199633452963018532025
   PubMed Web of Science ®Google Scholar
• BadeschDBTapsonVFMcgoonMDContinuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial[J]Ann Intern Med2000132642543410733441
   PubMed Web of Science ®Google Scholar
• GalieNSeegerWNaeijeRComparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension[J]J Am Coll Cardiol20044312 Suppl S81S88S15194183
   PubMed Web of Science ®Google Scholar
• ChannickRNSimonneauGSitbonOEffects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study[J]Lancet200135892881119112311597664
   PubMed Web of Science ®Google Scholar
• GalieNBadeschDOudizRAmbrisentan therapy for pulmonary arterial hypertension[J]J Am Coll Cardiol200546352953516053970
   PubMed Web of Science ®Google Scholar
• GalieNOlschewskiHOudizRJAmbrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2[J]Circulation2008117233010301918506008
   PubMed Web of Science ®Google Scholar
• McgoonMDFrostAEOudizRJAmbrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities[J]Chest2009135112212918812445
   PubMed Web of Science ®Google Scholar
• BolliMHBossCBinkertCThe discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N′-p ropylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist[J]J Med Chem201255177849786122862294
   PubMed Web of Science ®Google Scholar
• IglarzMBinkertCMorrisonKPharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist[J]J Pharmacol Exp Ther2008327373674518780830
   PubMed Web of Science ®Google Scholar
• PulidoTAdzerikhoIChannickRNMacitentan and morbidity and mortality in pulmonary arterial hypertension[J]N Engl J Med2013369980981823984728
   PubMed Web of Science ®Google Scholar
• LavelleASugrueRLawlerGSitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension[J]Eur Respir J200934377077119720812
   PubMed Web of Science ®Google Scholar
• JingZCYuZXShenJYVardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study[J]Am J Respir Crit Care Med2011183121723172921471085
   PubMed Web of Science ®Google Scholar
• JingZCJiangXWuBXVardenafil treatment for patients with pulmonary arterial hypertension: a multicentre, open-label study[J]Heart200995181531153619549620
   PubMed Web of Science ®Google Scholar
• GhofraniHAVoswinckelRReichenbergerFDifferences in hemodynamic and oxygenation responses to three different phospho-diesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study[J]J Am Coll Cardiol20044471488149615464333
   PubMed Web of Science ®Google Scholar
• GalieNGhofraniHATorbickiASildenafil citrate therapy for pulmonary arterial hypertension[J]N Engl J Med2005353202148215716291984
   PubMed Web of Science ®Google Scholar
• GalieNBrundageBHGhofraniHATadalafil therapy for pulmonary arterial hypertension[J]Circulation2009119222894290319470885
   PubMed Web of Science ®Google Scholar
• GhofraniHAGalieNGrimmingerFRiociguat for the treatment of pulmonary arterial hypertension[J]N Engl J Med2013369433034023883378
   PubMed Web of Science ®Google Scholar
• MielniczukLMSwistonJRMehtaSRiociguat: a novel therapeutic option for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension[J]Can J Cardiol201430101233124025154043
   PubMed Web of Science ®Google Scholar
• BishopBMRiociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension[J]Am J Health Syst Pharm201471211839184425320133
   PubMed Web of Science ®Google Scholar
• BarstRJRubinLJLongWAA comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension[J]N Engl J Med199633452963018532025
   PubMed Web of Science ®Google Scholar
• MclaughlinVVShillingtonARichSSurvival in primary pulmonary hypertension: the impact of epoprostenol therapy[J]Circulation2002106121477148212234951
   PubMed Web of Science ®Google Scholar
• SitbonOHumbertMNunesHLong-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival[J]J Am Coll Cardiol200240478078812204511
   PubMed Web of Science ®Google Scholar
• BadeschDBMclaughlinVVDelcroixMProstanoid therapy for pulmonary arterial hypertension[J]J Am Coll Cardiol20044312 Suppl S56S61S15194179
   PubMed Web of Science ®Google Scholar
• TapsonVFTorresFKermeenFOral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial[J]Chest201214261383139022628490
   PubMed Web of Science ®Google Scholar
• TapsonVFJingZCXuKFOral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial[J]Chest2013144395295823669822
   PubMed Web of Science ®Google Scholar
• JingZCParikhKPulidoTEfficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial[J]Circulation2013127562463323307827
   PubMed Web of Science ®Google Scholar
• BarstRJMcgoonMMclaughlinVBeraprost therapy for pulmonary arterial hypertension[J]J Am Coll Cardiol200341122119212512821234
   PubMed Web of Science ®Google Scholar
• GalieNHumbertMVachieryJLEffects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial[J]J Am Coll Cardiol20023991496150211985913
   PubMed Web of Science ®Google Scholar
• MontaniDPerrosFGambaryanNC-kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension[J]Am J Respir Crit Care Med2011184111612321471108
   PubMed Web of Science ®Google Scholar
• PerrosFMontaniDDorfmullerPPlatelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension[J]Am J Respir Crit Care Med20081781818818420966
   PubMed Web of Science ®Google Scholar
• SchermulyRTDonyEGhofraniHAReversal of experimental pulmonary hypertension by PDGF inhibition[J]J Clin Invest2005115102811282116200212
   PubMed Web of Science ®Google Scholar
• GhofraniHAMorrellNWHoeperMMImatinib in pulmonary arterial hypertension patients with inadequate response to established therapy[J]Am J Respir Crit Care Med201018291171117720581169
   PubMed Web of Science ®Google Scholar
• HoeperMMBarstRJBourgeRCImatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study[J]Circulation2013127101128113823403476
   PubMed Web of Science ®Google Scholar
• SimonneauGTorbickiAHoeperMMSelexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension[J]Eur Respir J201240487488022362844
   PubMed Web of Science ®Google Scholar
• LiuCChenJEndothelin receptor antagonists for pulmonary arterial hypertension[J]Cochrane Database Syst Rev20063D4434
   Google Scholar
• MclaughlinVVSitbonOBadeschDBSurvival with first-line bosentan in patients with primary pulmonary hypertension[J]Eur Respir J200525224424915684287
   PubMed Web of Science ®Google Scholar
• RubinLJBadeschDBBarstRJBosentan therapy for pulmonary arterial hypertension[J]N Engl J Med20023461289690311907289
   PubMed Web of Science ®Google Scholar
• GalieNRubinLHoeperMTreatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial[J]Lancet200837196302093210018572079
   PubMed Web of Science ®Google Scholar
• OwenKCrossDMDerziMAn overview of the preclinical toxicity and potential carcinogenicity of sitaxentan (Thelin(R)), a potent endothelin receptor antagonist developed for pulmonary arterial hypertension[J]Regul Toxicol Pharmacol20126419510322683289
   PubMed Web of Science ®Google Scholar
• McgoonMDFrostAEOudizRJAmbrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities[J]Chest2009135112212918812445
   PubMed Web of Science ®Google Scholar
• SastryBKNarasimhanCReddyNKClinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study[J]J Am Coll Cardiol20044371149115315063421
   PubMed Web of Science ®Google Scholar
• BarstRJIvyDDGaitanGA randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension[J]Circulation2012125232433422128226
   PubMed Web of Science ®Google Scholar
• BarstRJBeghettiMPulidoTSTARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension[J]Circulation2014129191914192324637559
   PubMed Web of Science ®Google Scholar
• YungDWidlitzACRosenzweigEBOutcomes in children with idiopathic pulmonary arterial hypertension[J]Circulation2004110666066515289375
   PubMed Web of Science ®Google Scholar
• LammersAEHislopAAFlynnYEpoprostenol treatment in children with severe pulmonary hypertension[J]Heart200793673974317065181
   PubMed Web of Science ®Google Scholar
• HislopAAMoledinaSFosterHLong-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children[J]Eur Respir J2011381707721177841
   PubMed Web of Science ®Google Scholar
• IvyDDRosenzweigEBLemarieJCLong-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings[J]Am J Cardiol201010691332133821029834
   PubMed Web of Science ®Google Scholar
• HaworthSGHislopAATreatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001–2006[J]Heart200995431231718952635
   PubMed Web of Science ®Google Scholar
• BarstRJMcgoonMDElliottCGSurvival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management[J]Circulation2012125111312222086881
   PubMed Web of Science ®Google Scholar
• van LoonRLRoofthooftMTDelhaasTOutcome of pediatric patients with pulmonary arterial hypertension in the era of new medical therapies[J]Am J Cardiol2010106111712420609658
   PubMed Web of Science ®Google Scholar
• BarstRJRubinLJMcgoonMDSurvival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin[J]Ann Intern Med199412164094158053614
   PubMed Web of Science ®Google Scholar
• PrakashAPerryCMBosentan[J]Am J Cardiovasc Drugs20022533534314727963
   PubMedGoogle Scholar
• BillmanGEAmbrisentan (Myogen)[J]Curr Opin Investig Drugs200231014831486
   PubMedGoogle Scholar
• ShapiroSMOudizRJCaoTPrimary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion[J]J Am Coll Cardiol19973023433499247503
   PubMed Web of Science ®Google Scholar
• Gomberg-MaitlandMOlschewskiHProstacyclin therapies for the treatment of pulmonary arterial hypertension[J]Eur Respir J200831489190118378784
   PubMed Web of Science ®Google Scholar
• LaliberteKArnesonCJeffsRPharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers[J]J Cardiovasc Pharmacol200444220921415243302
   PubMed Web of Science ®Google Scholar
• WalkerDKAcklandMJJamesGCPharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man[J]Xenobiotica199929329731010219969
   PubMed Web of Science ®Google Scholar
• PalmieriEAAffusoFFazioSTadalafil in primary pulmonary arterial hypertension[J]Ann Intern Med2004141974374415520445
   PubMed Web of Science ®Google Scholar
• FreyRMuckWUngerSSingle-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers[J]J Clin Pharmacol200848892693418519919
   PubMed Web of Science ®Google Scholar
• WarrenJBHigenbottamTCaution with use of inhaled nitric oxide[J]Lancet199634890286296308782748
   PubMed Web of Science ®Google Scholar
• HoeperMMOlschewskiHGhofraniHAA comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group[J]J Am Coll Cardiol200035117618210636277
   PubMed Web of Science ®Google Scholar
• OlschewskiHWalmrathDSchermulyRAerosolized prostacyclin and iloprost in severe pulmonary hypertension[J]Ann Intern Med199612498208248610951
   PubMed Web of Science ®Google Scholar
• OlschewskiHGhofraniHAWalmrathDInhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis[J]Am J Respir Crit Care Med1999160260060710430735
   PubMed Web of Science ®Google Scholar
• GesslerTSchmehlTHoeperMMUltrasonic versus jet nebulization of iloprost in severe pulmonary hypertension[J]Eur Respir J2001171141911307743
   PubMed Web of Science ®Google Scholar
• VoswinckelREnkeBReichenbergerFFavorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies[J]J Am Coll Cardiol20064881672168117045906
   PubMed Web of Science ®Google Scholar
• SimonneauGBarstRJGalieNContinuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial[J]Am J Respir Crit Care Med2002165680080411897647
   PubMed Web of Science ®Google Scholar
• GalieNManesABranziAProstanoids for pulmonary arterial hypertension[J]Am J Respir Med20032212313714720012
   PubMedGoogle Scholar
• Lopez-MeseguerMBerasteguiCMonforteVInhaled iloprost plus oral sildenafil in patients with severe pulmonary arterial hypertension delays the need for lung transplantation[J]Transplant Proc20134562347235023953548
   PubMed Web of Science ®Google Scholar
• OnenZPSayinTAkkocaYO[Efficacy of long-term oral mono-therapy and additional effect of inhaled iloprost in patients with severe idiopathic pulmonary arterial hypertension][J]Anadolu Kardiyol Derg201010545846020929705
   PubMedGoogle Scholar
• BaldiFFusoLArrighiEOptimal management of pulmonary arterial hypertension: prognostic indicators to determine treatment course[J]Ther Clin Risk Manag20141082583925328398
   PubMed Web of Science ®Google Scholar
• MacchiaAMarchioliRMarfisiRA meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology[J]Am Heart J200715361037104717540207
   PubMed Web of Science ®Google Scholar
• OlschewskiHSimonneauGGalieNInhaled iloprost for severe pulmonary hypertension[J]N Engl J Med2002347532232912151469
   PubMed Web of Science ®Google Scholar
• RubinLJBadeschDBFlemingTRLong-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study[J]Chest201114051274128321546436
   PubMed Web of Science ®Google Scholar
• LangIGomez-SanchezMKneusslMEfficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension[J]Chest200612961636164316778286
   PubMed Web of Science ®Google Scholar
• BarstRJGalieNNaeijeRLong-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil[J]Eur Respir J20062861195120316899485
   PubMed Web of Science ®Google Scholar
• BadeschDBChampionHCSanchezMADiagnosis and assessment of pulmonary arterial hypertension[J]J Am Coll Cardiol2009541 SupplS55S6619555859
   PubMed Web of Science ®Google Scholar
• HumbertMLauEMMontaniDAdvances in therapeutic interventions for patients with pulmonary arterial hypertension[J]Circulation2014130242189220825602947
   PubMed Web of Science ®Google Scholar
• MclaughlinVVOudizRJFrostARandomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension[J]Am J Respir Crit Care Med2006174111257126316946127
   PubMed Web of Science ®Google Scholar
• HoeperMMLeuchteHHalankMCombining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension[J]Eur Respir J200628469169417012628
   PubMed Web of Science ®Google Scholar
• HumbertMBarstRJRobbinsIMCombination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2[J]Eur Respir J200424335335915358690
   PubMed Web of Science ®Google Scholar
• MclaughlinVVBenzaRLRubinLJAddition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial[J]J Am Coll Cardiol201055181915192220430262
   PubMed Web of Science ®Google Scholar
• SimonneauGRubinLJGalieNAddition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial[J]Ann Intern Med2008149852153018936500
   PubMed Web of Science ®Google Scholar
• KempKSavaleLO’CallaghanDSUsefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study[J]J Heart Lung Transplant201231215015822138355
   PubMed Web of Science ®Google Scholar
• SitbonOJaisXSavaleLUpfront triple combination therapy in pulmonary arterial hypertension: a pilot study[J]Eur Respir J20144361691169724627535
   PubMed Web of Science ®Google Scholar
• KeoghAMMayerEBenzaRLInterventional and surgical modalities of treatment in pulmonary hypertension[J]J Am Coll Cardiol2009541 SupplS67S7719555860
   PubMed Web of Science ®Google Scholar
• LordanJLCorrisPAPulmonary arterial hypertension and lung transplantation[J]Expert Rev Respir Med20115344145421702664
   PubMed Web of Science ®Google Scholar
• GrantonJMercierODe PerrotMManagement of severe pulmonary arterial hypertension[J]Semin Respir Crit Care Med201334570071324037636
   PubMed Web of Science ®Google Scholar
• HoeperMMGrantonJIntensive care unit management of patients with severe pulmonary hypertension and right heart failure[J]Am J Respir Crit Care Med2011184101114112421700906
   PubMed Web of Science ®Google Scholar